⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 30, 2024EClinicalMedicineOpen Access

GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review

Nasreen Alfaris Stephanie Waldrop Veronica Johnson Brunna Cristina Bremer Boaventura Karla N. Kendrick Fatima Cody Stanford

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

National Institutes of HealthNIDDKU24 DK132733 (FCS), UE5 DK137285 (FCS), and P30 DK040561 (FCS).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Alfaris et al. (2024) studied this question.

synapsesocial.com/papers/69d6c52cfca0359822aa865c https://doi.org/10.1016/j.eclinm.2024.102782

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021Original Research · 2023 · 4,721 citations
2Physiological Integration of Taste and MetabolismOriginal Research · 2024 · 36 citations
3Identification and Characterization of GLP-1 Receptor–Expressing Cells Using a New Transgenic Mouse ModelOriginal Research · 2013 · 469 citations
4Glucose Sensing Mediated by Portal Glucagon-Like Peptide 1 Receptor Is Markedly Impaired in Insulin-Resistant Obese AnimalsOriginal Research · 2020 · 18 citations
5Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.Original Research · 1993 · 1,651 citations

More related papers

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes2013
Brain reward‐system activation in response to anticipation and consumption of palatable food is altered by glucagon‐like peptide‐1 receptor activation in humans2015
Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes2005

More from EClinicalMedicine

A multimodal digital NeuroMarker platform with composite and domain-level validity for identification of mild cognitive impairment: a cross-sectional studyFri,
Defining the clinical benefits of disease-modifying therapy in people living with spinal muscular atrophy who require permanent ventilation: a UK-based modified Delphi consensus processSat,